ISRCTN24921472 https://doi.org/10.1186/ISRCTN24921472

Study of oral MEK inhibitor selumetinib (AZD6244 hyd-sulphate) in combination with highly active anti retroviral therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS)

Submission date 02/03/2012	**Recruitment status** Stopped	[X] Prospectively registered [_] Protocol
Registration date 02/03/2012	**Overall study status** Stopped	[_] Statistical analysis plan [X] Results
Last Edited 23/05/2025	**Condition category** Cancer	[_] Individual participant data [_] Record updated in last year

Plain English summary of protocol
Current plain English summary as of 13/02/2019:
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-selumetinib-people-kaposis-sarcoma-scart

Previous plain English summary:
http://cancerhelp.cancerresearchuk.org/trials/a-trial-looking-selumetinib-people-kaposis-sarcoma-scart

Study website
https://www.birmingham.ac.uk/research/crctu/trials/scart

Contact information

Type(s)
Scientific

Contact name
Dr Robin Young

Contact details
Weston Park Hospital
Sheffield
United Kingdom
S10 2SJ
0114 226 5000
r.j.young@sheffield.ac.uk

Type(s)
Scientific

Contact name
Dr Joshua Savage

ORCID ID
https://orcid.org/0000-0003-0599-0245

Contact details
Early Drug Development Team Leader
Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
United Kingdom
B15 2TT
+44 (0)121 415 8421
j.savage.1@bham.ac.uk

Type(s)
Public

Contact name
Dr SCART Team

Contact details
Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
United Kingdom
B15 2TT
+44 (0) 121 414 6754
scart@contacts.bham.ac.uk

Additional identifiers

EudraCT/CTIS number
2011-003099-35

IRAS number

ClinicalTrials.gov number
NCT01752569

Secondary identifying numbers
11876

Study information

Scientific Title
Phase I/II study of oral MEK inhibitor selumetinib (AZD6244 hyd-sulphate) in combination with highly active anti retroviral therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS)

Acronym
SCART

Study objectives
Cancer is a leading cause of death in individuals living with HIV, and Kaposi's sarcoma (KS) remains the commonest HIV-associated cancer. KS results from co-infection with HIV and another virus, HHV-8. Laboratory studies have shown that HHV-8 viral proteins stimulate intracellular signalling pathways within KS lesions which promotes their growth. Selumetinib targets these signalling pathways and may therefore be a useful new therapy for KS.

SCART is a national multi-centre study. The objectives of the SCART trial are to determine a safe and tolerable dose for selumetinib in combination with HIV anti-retroviral therapy, and to determine whether selumetinib reduces KS lesions in HIV positive patients.

More details can be found at http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=11876 (link no longer works as of 13/02/2019)

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved 10/11/2011, Yorkshire and the Humber - Leeds East (NHSBT Newcastle Blood Donor Centre
Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)207 1048171, (0)207 104 8141; leedseast.rec@hra.nhs.uk), ref: 11/YH/0373

Study design
Non-randomized interventional study

Primary study design
Interventional

Secondary study design
Non randomised study

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Sarcoma

Interventions
Selumetinib, Orally bioavailable, selective inhibitor of MEK 1/2, inhibiting the phosphorylation of ERK 1/2

Patients will undergo 6 x 21-day (3-weekly) cycles of treatment. There is a screening visit following by visits every at the end of every cycle. In Phase I during cycle 1 there are weekly visits. Visits involve clinical examination, periodic clinical photographs of lesions, haematology /biochemistry, blood samples taken for translational studies. CT, ECHO or Multi Gated Acquisition Scan (MUGA). Ophthalmologic exam will occur during screening. Further assessments of this nature will only be performed if judged clinically necessary. Patients will have a follow-up visit every 12 weeks for 12 months to record changes in lesions by clinical photographs.

Intervention Type
Drug

Phase
Phase I/II

Drug/device/biological/vaccine name(s)
Selumetinib

Primary outcome measure
Objective response rates; Timepoint(s): Phase I and II

Secondary outcome measures
1. HAART Drug Levels; Timepoint(s): Phase I
2. HIV control; Timepoint(s): Phase I and II
3. Number of selumetinib cycles completed; Timepoint(s): Phase I and II
4. PBMC Sub-study; Timepoint(s): Phase I and II; PD measures of selumetinib in combination with HAART; Timepoint(s): Phase I and II
5. Progression free survival rate; Timepoint(s): Phase I and II - 6 months post ccompletion of study
6. Selumetinib and metabolite serum levels; Timepoint(s): phase I
7. Toxicity; Timepoint(s): Phase I and II

Overall study start date
12/03/2012

Completion date
31/01/2018

Reason abandoned (if study stopped)
Participant recruitment issue

Eligibility

Key inclusion criteria
1. Human immunodeficiency virus (HIV) positive and established on a HAART regimen for >=3 months
2. Histologically confirmed KS
3. Measurable disease according to AIDS Clinical Trials Group (ACTG) criteria
4. Evidence of disease progression in the past 6 months, without anticancer treatment since progression
5. Progressive cutaneous or nodal KS not requiring chemotherapy or progressive KS following cytotoxic chemotherapy
6. Adequate haematological function:
6.1. Haemoglobin = 9 g/dL
6.2. Absolute neutrophil count = 1.5 x 10 9/L
6.3. Platelets = 100 x 10 9/L
7. Adequate hepatic function:
7.1. Serum bilirubin = 1.5 x upper limit of normal (ULN)
7.2. Alanine aminotransferase (ALT) = 2.5 x ULN
7.3. Aspartate aminotransferase (AST) = 2.5 x ULN
8. Adequate renal function:
8.1. Serum creatinine clearance > 50 ml/min (Cockcroft-Gault formula or 24 hour urine collection)
8.2. Left ventricular function >50% normal
9. Age = 18 years.
10. Eastern Cooperative Oncology Group (ECOG) performance status > 2
11. For selumetinib, women of child bearing age and child bearing potential must have a negative pregnancy test prior to study entry and be using an adequate contraception method, which must be continued while on treatment and for at least 4 weeks after the study treatment has ended
12. Male patients must agree to use an effective contraception method while on treatment and for at least 16 weeks after the study treatment has ended (barrier contraception is recommended for all individuals living with HIV).
13. Written informed consent

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Sex
Both

Target number of participants
Planned Sample Size: 37; UK Sample Size: 37

Total final enrolment
19

Key exclusion criteria

1. HIV viral load > 200 copies/ml
2. Any previous treatment with a Ras, Raf or MEK inhibitor
3. Active opportunistic infections.
4. Known hepatitis B, hepatitis C
5. Clinical evidence of uncontrolled hypertension (systolic BP > 150 mmHg or diastolic BP > 90 mmHg on 2 readings = 1 hour apart))
6. Clinical evidence of heart failure (= New York Heart Association [NYHA] Class II)
7. Clinical evidence of atrial fibrillation (heart rate > 100 bpm) or unstable ischaemic heart disease (MI within 6 months prior to starting treatment or angina requiring the use of nitrates > once weekly)
8. Major surgery within 4 weeks prior to starting selumetinib
9. Evidence of any psychological, familial, sociological or geographical condition potentially hampering protocol compliance
10. Clinical judgement by the Investigator that the patient should not participate in the study
11. Refractory nausea, vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease) or significant bowel resection that would preclude adequate absorption
12. Treatment with any investigational product within 28 days of registration
13. Pregnant or breastfeeding women

Date of first enrolment
12/03/2012

Date of final enrolment
31/12/2016

Locations

Countries of recruitment
England

Scotland

United Kingdom

Study participating centre
Weston Park Hospital
Whitham Road
Sheffields
United Kingdom
S10 2SJ

Study participating centre
Royal Free London NHS Foundation Trust Royal Free Hospital
Pond Street

London
United Kingdom
NW3 2QG

Study participating centre
Royal Sussex County Hospital
Eastern Road
Brighton
United Kingdom
BN2 5BE

Study participating centre
Chelsea and Westminster NHS Foundation Trust
369 Fulham Road
London
United Kingdom
SW10 9NH

Study participating centre
Beatson West of Scotland Cancer Centre
1053 Great Western Road
Glasgow
United Kingdom
G12 0YN

Study participating centre
Christie Hospital
Wilmslow Road
Manchester
United Kingdom
M20 4BX

Sponsor information

Organisation
Sheffield Teaching Hospitals NHS Trust (UK)

Sponsor details

Research Department
11 Broomfield Road
Sheffield
England
United Kingdom
S10 2SE

Sponsor type
Hospital/treatment centre

ROR
https://ror.org/018hjpz25

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK (CRUK) (UK)

Alternative Name(s)
CR_UK, Cancer Research UK - London, CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Planned publication in a high-impact peer-reviewed journal

Intention to publish date
01/06/2023

Individual participant data (IPD) sharing plan
Current IPD sharing statement as of 01/02/2023:
The datasets generated during and/or analysed during the current study are/will be available upon request. Scientifically sound proposals from appropriately qualified researchers will be

considered for data sharing. Requests should be made by returning a Data Sharing Request Form to newbusiness@trials.bham.ac.uk; this captures the research requirements, statistical analysis plan, and intended publication schedule. Requests will be reviewed by the Cancer Research UK Clinical Trials Unit (CRCTU) Directors in discussion with the Chief Investigator (CI), Trial Management Group (TMG), independent Data Monitoring Committee (DMC) and Sponsor (Sheffield Teaching Hospitals NHS Foundation Trust). They will consider the scientific validity of the request, qualifications of the researchers, CI, TMG & TSC views, consent arrangements, the practicality of anonymizing the requested data and contractual obligations. If supportive of the request, and where not already obtained, Sponsor consent for data transfer will be sought before notifying applicants of the outcome. It is anticipated that applicants will be notified within 3 months of receipt of the original request.

Previous IPD sharing statement:
The data-sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary
Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results	version 1.0a	16/02/2023	16/02/2023	No	No
HRA research summary			28/06/2023	No	No
Results article		19/03/2025	25/03/2025	Yes	No
Plain English results			23/05/2025	No	Yes